Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
18.56
+0.17 (+0.92%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Why Can't You Find Adderall? Inside the Ongoing Shortage of ADHD Medication In US
September 12, 2023
Last year, Teva Pharmaceutical Industries Ltd (NYSE: TEVA), the primary producer of Adderall, faced shortages
Via
Benzinga
TEVA - A Pharma Stock To Watch
September 11, 2023
TEVA is one of the few instruments that has handily cleared its July 6-month calendar range high. The 50 daily moving average is about to cross or golden cross the 200-DMA and enter a bullish phase.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
September 11, 2023
Via
Benzinga
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug
September 11, 2023
This story was first published on the Benzinga India portal.
Via
Benzinga
Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug
September 07, 2023
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Teva Takes A Run At Its 200-Day Line After Second-Quarter Beat And Raise
August 02, 2023
The company also raised the lower boundary of its guidance for full-year sales.
Via
Investor's Business Daily
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
S&P Slashes Ratings Of Five US Banks, SEC Fines Fintech Adviser Titan For Misleading Crypto Claims, Microsoft Modifies Activision Blizzard Purchase: Today's Top Stories
August 22, 2023
Benzinga
Via
Benzinga
Topics
Regulatory Compliance
Stocks
Exposures
Legal
Regulatory
US Equities
Big Pharma Price-Fixing: Teva and Glenmark's $255M Settlement Shines Light on Industry Issues
August 22, 2023
Drugmaker Teva Pharmaceutical Industries Limited (NYSE: TEVA) has
Via
Benzinga
Teva Settles Price Fixing Charges With U.S. DOJ
August 21, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning
August 21, 2023
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated
Via
Benzinga
Exposures
Product Safety
Supreme Court Halts Purdue Pharma's $6B Settlement: Sackler Family's Shield From Opioid Lawsuits Challenged
August 10, 2023
On Thursday, the Supreme Court temporarily blocked a $6-billion bankruptcy settlement by Purdue Pharma, the maker of the opioid OxyContin, that would shield the Sackler family from civil lawsuits...
Via
Benzinga
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Legal
Teva Pharmaceutical, Marathon Oil And 2 Other Stocks Insiders Are Selling
August 10, 2023
The Nasdaq 100 closed lower by over 1% on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
August 02, 2023
Gainers WaveDancer, Inc. (NASDAQ: WAVD) shares climbed 86% to $0.5505. Tellenger, a subsidiary of Wavedancer, Inc., won a seven-year U.S. government contract.
Via
Benzinga
Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript
August 02, 2023
TEVA earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
August 02, 2023
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Wednesday. Here are some big stocks recording gains in today’s session. Powell Industries, Inc. (NASDAQ: POWL) shares jumped...
Via
Benzinga
Teva Pharma's Stock Soars On Q2 Profit Beat, Highlights Strong Growth From Austedo
August 02, 2023
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q2 sales reached $3.88 billion, up 2% Y/Y (4% on constant currency), slightly beating the
Via
Benzinga
Teva Reports Second Quarter 2023 Financial Results
August 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
July 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
July 26, 2023
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen
Via
Benzinga
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Alvotech
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
July 11, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
July 06, 2023
Via
Benzinga
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
July 05, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva's Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit
July 05, 2023
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.
Via
Benzinga
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
June 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Geopolitical Risks Prevail
June 27, 2023
A discussion about current geopolitical risks and their impact on commodity and stock markets.
Via
Talk Markets
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
June 21, 2023
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.